✦ LIBER ✦

Benefit of taxanes as adjuvant chemotherapy for early breast cancer : Pooled analysis of 15,500 patients

✍ Scribed by Emilio Bria; Cecilia Nistico; Federica Cuppone; Paolo Carlini; Mariangela Ciccarese; Michele Milella; Guido Natoli; Edmondo Terzoli; Francesco Cognetti; Diana Giannarelli

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 200 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21886

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Taxanes as primary chemotherapy for earl

Taxanes as primary chemotherapy for early breast cancer : Meta-analysis of randomized trials

✍ Federica Cuppone; Emilio Bria; Paolo Carlini; Michele Milella; Alessandra Felici 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

## Abstract ## BACKGROUND. In patients with locally advanced and operable breast cancer, neoadjuvant chemotherapy has been demonstrated to increase the chance of breast‐conserving surgery (BCS) when compared with adjuvant treatment; moreover, patients who achieve a pathologic complete response (pC

Taxanes with anthracyclines as first-lin

Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma : Pooled analysis of 2805 patients

✍ Emilio Bria; Diana Giannarelli; Alessandra Felici; William P. Peters; Cecilia Ni 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

Benefit and projected cost-effectiveness

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer

✍ Bruce E. Hillner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio

Assessment of highly angiogenic and diss

Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse

✍ Alexandra Giatromanolaki; Michael I. Koukourakis; Stelios Kakolyris; Dimitris Ma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 118 KB 👁 1 views

## Abstract The assessment of tumor molecular features in combination with the detection of occult malignant cells may provide important clinical information, beyond the standard staging of breast cancer. Using a nested RT‐PCR technique, we assessed prospectively the presence of cytokeratin‐19 (CK1

The impact of tumor progesterone recepto

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer : A decision analysis

✍ Rinaa S. Punglia; Karen M. Kuntz; Eric P. Winer; Jane C. Weeks; Harold J. Burste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views

Decreased immunoreactivity for p27 prote

Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status : Results from International Breast Cancer Study Group Trial V

✍ Vito J. Spataro; Heather Litman; Giuseppe Viale; Fausto Maffini; Michele Masullo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to clarify the prognostic and predictive value of immunoreactivity for the cyclin‐dependent kinase inhibitor p27(Kip1) in patients with early‐stage breast carcinoma and to investigate its relation with clinicopathologic features and other m